Research

Two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients, according to a new study by investigators at Weill Cornell Medicine, the University of Pennsylvania, and Medidata AI.

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research.

A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.

Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to novel therapeutic strategies for thwarting or eliminating HIV.

Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. 

Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.

Dr. Margaret McNairy, an associate professor of medicine in the Division of General Internal Medicine, has been selected as an Emerging Leader in Health and Medicine (ELHM) Scholar by the National Academy of Medicine.

Endothelial cells with a distinct gene-expression signature play a key role in the development and repair of blood vessels throughout life, according to a new study by Weill Cornell Medicine investigators. 

A multinational team led by Weill Cornell Medicine investigators developed a test that will help measure the persistence of HIV in people affected by viral strains found predominantly in Africa—a vital tool in the search for an HIV cure that will benefit patients around the world.

A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).

Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to an individual’s liver or to another organ.

Awards, honors and achievements for the month of June.

Vaccinating mothers against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours—sometimes more than a day—in a reversible intermediate state, according to a discovery by researchers at Weill Cornell Medicine. 

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer to the bone in men with prostate cancer at early stages of the disease.

The transition to menopause is marked by a progressively higher density of estrogen receptors (ER) on brain cells, a measure that remains elevated in women up to their mid-60s, according to a new brain imaging study led by researchers at Weill Cornell Medicine.

The 2024 Business Plan Challenge accelerator program culminated in a pitch competition with five finalist teams putting their knowledge and marketing skills to the test. 

Dr. Ashley Laughney, an assistant professor of physiology and biophysics at Weill Cornell Medicine, has won a 2024 Pershing Square Sohn Prize for Young Investigators in Cancer Research.

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center and Memorial Sloan Kettering Cancer Center.

Dr. Mohammad Arifuzzaman, a postdoctoral associate at Weill Cornell Medicine, has been awarded a 2024 Tri-Institutional Breakout Award for Junior Investigators.